Cargando…

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer

Detalles Bibliográficos
Autor principal:	Voutsadakis, Ioannis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488872/ https://www.ncbi.nlm.nih.gov/pubmed/31061869 http://dx.doi.org/10.1016/j.gore.2016.11.005

Ejemplares similares

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
por: Škof, Erik, et al.
Publicado: (2016)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Prognostic model for the exemption of adjuvant chemotherapy in stage IIIC endometrial cancer patients
por: Yang, Xi-Lin, et al.
Publicado: (2022)

D2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy
por: Peng, Jin, et al.
Publicado: (2016)

Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy
por: Mozarowski, Paul, et al.
Publicado: (2021)

Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer
por: Hoff, John, et al.
Publicado: (2014)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer
por: Forde, Gareth K, et al.
Publicado: (2016)

Stage IIIC endometrial cancer review: Current controversies in adjuvant therapy
por: Buras, Andrea L., et al.
Publicado: (2021)

Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
por: Dikken, Johan L, et al.
Publicado: (2011)

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
por: Slagter, Astrid E., et al.
Publicado: (2018)

A multi-institutional analysis of sequential versus ‘sandwich’ adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma
por: Onal, Cem, et al.
Publicado: (2018)

Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer
por: Lim, Myong Cheol, et al.
Publicado: (2017)

Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study
por: Kagabu, Masahiro, et al.
Publicado: (2021)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery()
por: Christie, Alan, et al.
Publicado: (2013)

Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer
por: De Bruyn, Christine, et al.
Publicado: (2021)

The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients
por: Kawahara, Naoki, et al.
Publicado: (2023)

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
por: Bloemendal, Martine, et al.
Publicado: (2019)

Dynamic Prediction of Resectability for Patients with Advanced Ovarian Cancer Undergoing Neo-Adjuvant Chemotherapy: Application of Joint Model for Longitudinal CA-125 Levels
por: Amroun, Koceila, et al.
Publicado: (2022)

Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer
por: Basi, Ali, et al.
Publicado: (2013)

Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer
por: Digklia, Antonia, et al.
Publicado: (2014)

Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study
por: Machida, Hiroko, et al.
Publicado: (2019)

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2016)

Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study
por: Zhou, Juan, et al.
Publicado: (2016)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
por: Findlay, John M., et al.
Publicado: (2016)

Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
por: Momtaz, Parisa, et al.
Publicado: (2017)

Low-dose immunotherapy as a potentiator to increase the response with neo-adjuvant chemotherapy in oral cancers
por: Rathinasamy, Narmadha, et al.
Publicado: (2023)

Treatment for Locally Resectable Stage IIIC1 Cervical Cancer: A Retrospective, Single-Institution Study
por: Kashima, Yoko, et al.
Publicado: (2023)

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover
por: Wilson, Caroline, et al.
Publicado: (2016)

Role of Laparotomy-based Parameters in Assessment of Optimal Primary Debulking Surgery and Long-term Outcomes in Patients with Stage IIIC Epithelial Ovarian Cancer
por: Zhou, Mingyi, et al.
Publicado: (2020)

Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
por: Bhattacharyya, G. S., et al.
Publicado: (2018)

Rectosigmoid resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team
por: Tozzi, Roberto, et al.
Publicado: (2021)

Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer
por: Chang, Alex Yuang-Chi, et al.
Publicado: (2016)

Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy
por: Mori, Miki, et al.
Publicado: (2019)

Changes in leukoencephalopathy and serum neurofilament after (neo)adjuvant chemotherapy for breast cancer
por: Schroyen, Gwen, et al.
Publicado: (2023)

Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity
por: Tozzi, Roberto, et al.
Publicado: (2019)

Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer
por: Aigner, Karl R., et al.
Publicado: (2021)

Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets
por: Voutsadakis, Ioannis A
Publicado: (2020)

Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC–IV ovarian cancer
por: Tozzi, Roberto, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j45gbforsqc55e41mfu6svv7p0